A clear comparison
Both names come up in growth hormone signalling research. Confirm the exact CJC sequence and modification before matching a paper to a vial.
The differences at a glance
Reference facts and current product information are separate below. On a small screen, swipe within the table; keyboard users can focus it and scroll with the arrow keys.
| Compare | CJC-1295 No DAC | Tesamorelin |
|---|---|---|
| Reference · material class | Research peptide under the No DAC supplier designation | GHRH analogue |
| Reference · identity and composition | Peptide supplied under the CJC-1295 No DAC designation. Exact sequence, terminal form and modifications require matching documentation. | Tesamorelin. Supplied form and exact specification require matching documentation. |
| Reference · research question | GHRH signalling research | Growth hormone & visceral fat |
| Reference · evidence and limitations | The cited long-acting CJC-1295 trial concerns DAC-containing material, not this No DAC listing. It does not establish the duration of action or effects of the supplied material. | Visceral fat is fat around internal organs. It is different from total body weight and from the fat under the skin. Findings in people with HIV-associated abdominal fat cannot simply be extended to every weight-management question. |
| Reference · source papers | Teichman et al. (2006): long-acting CJC-1295 trial | Falutz et al. (2007): tesamorelin in people with HIV and abdominal fat accumulation |
| Product · current sizes and prices | 5 mg · $49.99 In stock10 mg · $69.99 In stock | 10 mg · $109.99 In stock20 mg · $179.99 In stock |
| Product · current stock | In stock | In stock |
| Product · supplied specification | Confirm form, identity and specification for the selected size. A field not reported remains unconfirmed. Product specifications | Confirm form, identity and specification for the selected size. A field not reported remains unconfirmed. Product specifications |
| Product · matching lot records | No matching published record. Check Lab Results | No matching published record. Check Lab Results |
| Product · information and availability | View available options | View available options |
Product figures come from the current WooCommerce listing in the store currency. Package milligrams are nominal material amounts, not doses. No report for another sample or lot is substituted for a matching record.
What to compare in the evidence
The long-acting CJC-1295 study used the DAC-containing analogue. Its findings cannot establish the kinetics of No DAC material. Tesamorelin is a distinct GHRH analogue and its clinical evidence is specific to that material and study population.
How to match the material to a report
Check the batch identifier and material identity on the product record. Keep the study material and the supplier documentation separate in your notes.
Common questions
Can the two materials be treated as interchangeable?
No. Confirm composition and the experiment’s specific endpoint before making a comparison.
Original sources
These papers support the specific mechanisms or study models discussed above. They do not test the current Peptide Place catalogue batches.
- PubMed 16352683 ↗
- Falutz et al. (2007): tesamorelin in people with HIV and abdominal fat accumulation ↗
Continue exploring
CJC-1295 No DAC: current options and full overview →
Reading the research in context
Tesamorelin is a growth hormone-releasing factor analogue. CJC-1295 No DAC is a supplier designation for a separate research material. The two names should stay separate in a literature search or batch record.
What the tesamorelin trials measured
Falutz and colleagues pooled two phase 3 placebo-controlled trials in people with HIV who were receiving antiretroviral therapy and had excess abdominal fat. The analysis examined changes in visceral adipose tissue in that population. It did not compare tesamorelin with CJC-1295 No DAC or test a Peptide Place vial.
How to read the CJC-1295 literature
Check the exact sequence, terminal form and whether the study material carries a drug affinity complex (DAC). A paper using a DAC-containing material cannot establish the same duration or effects for a No DAC material. Confirm identity from the supplied documentation before matching a batch to a published method.
Original research and related material
Profiles and documentation guides
First, understand the growth hormone signal
The pituitary is a small gland at the base of the brain. It releases growth hormone in response to signals, including growth hormone-releasing hormone, or GHRH. GHRH acts through its receptor on cells in the pituitary. Growth hormone then influences other tissues and signals, including production of insulin-like growth factor 1, usually shortened to IGF-1.
Stimulating a signal is different from supplying growth hormone itself. The response depends on the biological system, not just the name of the compound. A change in a hormone measurement also does not establish a change in strength, lifespan or general wellbeing.
Where tesamorelin fits
Tesamorelin is a GHRH analogue, a molecule designed with a relationship to the natural signal. Its clinical evidence includes studies in a defined population with HIV-associated abdominal fat accumulation. Those studies should be described within that setting rather than turned into a general “anti-ageing” claim.
CJC-1295 No DAC: the naming problem matters
DAC means drug affinity complex. It refers to a modification associated with prolonged activity in the studied CJC-1295 material. “No DAC” tells you that this feature is absent, but a catalogue name alone still does not confirm the full sequence and modifications of a supplied material.
The 2006 Teichman study examined long-acting CJC-1295 in healthy adults and measured growth hormone and IGF-1 responses. It should not be used as direct evidence for the duration or clinical effects of a No DAC product. Read Teichman et al.
What to match in the methods
Look for the full material description, sequence or modifications, formulation and analytical information. Similar GHRH-related terminology does not mean two molecules have the same persistence, exposure or clinical evidence. This is why our comparison keeps CJC-1295 No DAC separate from CJC-1295 with DAC.
Clinical evidence and Canadian status are different checks
Falutz and colleagues’ tesamorelin trial studied HIV-associated abdominal fat accumulation. It provides evidence for its stated population and outcomes, not a direct clinical comparison with CJC-1295 No DAC. Read the original trial.
For Canadian availability, check the finished drug record rather than assume a US indication applies here. In November 2026, the Canadian database records examined for Egrifta were cancelled post-market for the 1 mg product and cancelled pre-market for the 2 mg product. These are dated, product-specific records, not approval of a research vial.
Can this comparison tell you which is better?
It can clarify identity, signalling and evidence. The cited studies do not provide a direct head-to-head clinical trial of tesamorelin versus CJC-1295 No DAC for a common outcome. Picking a winner from separate hormone measurements would go beyond that evidence.
Where should a beginner read next?
The growth hormone secretagogue guide explains the wider signalling group. The tesamorelin research profile follows the individual compound, and How to Read Peptide Research explains how to compare endpoints.
Keep the formulation distinction in your notes
The DAC distinction belongs with the exact material, not just its display name. Use the specification worksheet and the evidence-reading checklist before carrying a result from one formulation to another.
